Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Neoplasms of the CNS

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 46 articles: HTML format

Single Articles

December 2022
1. CHEN PC, Yeh YM, Chu CT, Su PF, et al
   HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study.
   Eur J Cancer. 2022;181:62-69.
   PubMed     Abstract available
   
   
   November 2022
2. DI GIACOMO AM, Mair MJ, Ceccarelli M, Anichini A, et al
   Immunotherapy for brain metastases and primary brain tumors.
   Eur J Cancer. 2022;179:113-120.
   PubMed     Abstract available
   
   
   
3. TESILEANU CMS, Vallentgoed WR, French PJ, van den Bent MJ, et al
   Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.
   Eur J Cancer. 2022;175:214-223.
   PubMed     Abstract available
   
   
   
4. TER MAAT LS, van Duin IAJ, Elias SG, van Diest PJ, et al
   Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review.
   Eur J Cancer. 2022;175:60-76.
   PubMed     Abstract available
   
   
   
5. SERRA-BELLVER P, Versluis JM, Oberoi HK, Zhou C, et al
   Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.
   Eur J Cancer. 2022;176:121-132.
   PubMed     Abstract available
   
   
   October 2022
6. MUELLER T, Laternser S, Guerreiro Stucklin AS, Gerber NU, et al
   Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience.
   Eur J Cancer. 2022;178:171-179.
   PubMed     Abstract available
   
   
   
7. WU F, Sun Y
   Re: Effect of glioma-derived immunoglobulin on biological function of glioma cells: The emerging roles of immunoglobulins in the tumor immune microenvironment.
   Eur J Cancer. 2022;178:34-36.
   PubMed    
   
   
   
8. LE RHUN E, Oppong FB, van den Bent M, Wick W, et al
   Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
   Eur J Cancer. 2022;178:13-22.
   PubMed     Abstract available
   
   
   September 2022
9. DUTRIAUX C, Robert C, Grob JJ, Mortier L, et al
   An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.
   Eur J Cancer. 2022;175:254-262.
   PubMed     Abstract available
   
   
   
10. WANG Y, Lian B, Si L, Mao L, et al
    Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I-III.
    Eur J Cancer. 2022;175:196-203.
    PubMed     Abstract available
    
    
    
11. VOGLIS S, Schaller V, Muller T, Gonel M, et al
    Maximal surgical tumour load reduction in immune-checkpoint inhibitor naive patients with melanoma brain metastases correlates with prolonged survival.
    Eur J Cancer. 2022;175:158-168.
    PubMed     Abstract available
    
    
    
12. TAIEB J, Svrcek M, Cohen R, Basile D, et al
    Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
    Eur J Cancer. 2022;175:136-157.
    PubMed     Abstract available
    
    
    
13. LV J, Chen S, Chen X, Xie J, et al
    Effect of glioma-derived immunoglobulin on biological function of glioma cells.
    Eur J Cancer. 2022;175:86-98.
    PubMed     Abstract available
    
    
    July 2022
14. TAN DSW, Kim SW, Ponce Aix S, Sequist LV, et al
    Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.
    Eur J Cancer. 2022;172:276-286.
    PubMed     Abstract available
    
    
    June 2022
15. SCHUBERT NA, Chen CY, Rodriguez A, Koster J, et al
    Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours.
    Eur J Cancer. 2022;170:196-208.
    PubMed     Abstract available
    
    
    May 2022
16. CHRISTOPOULOS P, Kluck K, Kirchner M, Luders H, et al
    The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.
    Eur J Cancer. 2022;170:106-118.
    PubMed     Abstract available
    
    
    
17. KREFT S, Glutsch V, Zaremba A, Schummer P, et al
    MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
    Eur J Cancer. 2022;167:32-41.
    PubMed     Abstract available
    
    
    February 2022
18. HAGEL C, Sloman V, Mynarek M, Petrasch K, et al
    Refining M1 stage in medulloblastoma: criteria for cerebrospinal fluid cytology and implications for improved risk stratification from the HIT-2000 trial.
    Eur J Cancer. 2022;164:30-38.
    PubMed     Abstract available
    
    
    
19. KELLER KM, Krausert S, Gopisetty A, Luedtke D, et al
    Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies.
    Eur J Cancer. 2022;162:107-117.
    PubMed     Abstract available
    
    
    January 2022
20. BALDINI C, Younan N, Castanon Alvarez E, Ammari S, et al
    Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials.
    Eur J Cancer. 2022;163:98-107.
    PubMed     Abstract available
    
    
    
21. SKAYEM C, Garcia G, Grill J, Aghakhani N, et al
    First case of a melanocytic intrabulbar brain tumour treated with bevacizumab.
    Eur J Cancer. 2022;162:206-208.
    PubMed    
    
    
    
22. STEINDL A, Brunner TJ, Heimbach K, Schweighart K, et al
    Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years.
    Eur J Cancer. 2022;162:170-181.
    PubMed     Abstract available
    
    
    November 2021
23. VASSELLA E, Kashani E, Zens P, Kundig A, et al
    Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations.
    Eur J Cancer. 2021;159:227-236.
    PubMed     Abstract available
    
    
    
24. SCHULPEN M, Visser O, Reedijk AMJ, Kremer LCM, et al
    Significant improvement in survival of advanced stage childhood and young adolescent cancer in the Netherlands since the 1990s.
    Eur J Cancer. 2021;157:81-93.
    PubMed     Abstract available
    
    
    October 2021
25. KARSCHNIA P, Le Rhun E, Vogelbaum MA, van den Bent M, et al
    The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy.
    Eur J Cancer. 2021;156:93-108.
    PubMed     Abstract available
    
    
    August 2021
26. GKEKAS I, Novotny J, Kaprio T, Beilmann-Lehtonen I, et al
    Colon cancer patients with mismatch repair deficiency are more likely to present as acute surgical cases.
    Eur J Cancer. 2021;157:1-9.
    PubMed     Abstract available
    
    
    
27. HILBERS ML, Dimitriou F, Lau P, Bhave P, et al
    Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Eur J Cancer. 2021;156:149-163.
    PubMed     Abstract available
    
    
    
28. LOMBARDI G, Del Bianco P, Brandes AA, Eoli M, et al
    Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial).
    Eur J Cancer. 2021;155:179-190.
    PubMed     Abstract available
    
    
    July 2021
29. LE DU F, Dieras V, Curigliano G
    The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer.
    Eur J Cancer. 2021;154:175-189.
    PubMed     Abstract available
    
    
    May 2021
30. CHORTI E, Kebir S, Ahmed MS, Keyvani K, et al
    Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
    Eur J Cancer. 2021;148:395-404.
    PubMed     Abstract available
    
    
    April 2021
31. VERBRUGGEN LC, Kok JL, Teepen JC, Janssens GO, et al
    Clinical characteristics of subsequent histologically confirmed meningiomas in long-term childhood cancer survivors: A Dutch LATER study.
    Eur J Cancer. 2021;150:240-249.
    PubMed     Abstract available
    
    
    
32. ZHENG MM, Tu HY, Yang JJ, Zhang XC, et al
    Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Eur J Cancer. 2021;150:23-30.
    PubMed     Abstract available
    
    
    
33. DIMITRIOU F, Zaremba A, Allayous C, Kahler KC, et al
    Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response.
    Eur J Cancer. 2021;149:37-48.
    PubMed     Abstract available
    
    
    
34. KARSCHNIA P, Vogelbaum MA, van den Bent M, Cahill DP, et al
    Evidence-based recommendations on categories for extent of resection in diffuse glioma.
    Eur J Cancer. 2021;149:23-33.
    PubMed     Abstract available
    
    
    March 2021
35. PARTANEN M, Anghelescu DL, Hall L, Schreiber JE, et al
    Longitudinal associations between exposure to anesthesia and neurocognitive functioning in pediatric medulloblastoma.
    Eur J Cancer. 2021;148:103-111.
    PubMed     Abstract available
    
    
    February 2021
36. GRAMATZKI D, Felsberg J, Hentschel B, Wolter M, et al
    Telomerase reverse transcriptase promoter mutation- and O(6)-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
    Eur J Cancer. 2021;147:84-94.
    PubMed     Abstract available
    
    
    
37. CLEMENT PMJ, Dirven L, Eoli M, Sepulveda-Sanchez JM, et al
    Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
    Eur J Cancer. 2021;147:1-12.
    PubMed     Abstract available
    
    
    
38. BERLANGA P, Pasqualini C, Potschger U, Sanguesa C, et al
    Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience.
    Eur J Cancer. 2021;144:1-8.
    PubMed     Abstract available
    
    
    January 2021
39. TOSONI A, Gatto L, Franceschi E, Di Nunno V, et al
    Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study.
    Eur J Cancer. 2021;145:171-178.
    PubMed     Abstract available
    
    
    December 2020
40. CARAMANNA I, Bottomley A, Drijver AJ, Twisk J, et al
    Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials.
    Eur J Cancer. 2020;144:162-168.
    PubMed     Abstract available
    
    
    November 2020
41. HONG AM, Waldstein C, Shivalingam B, Carlino MS, et al
    Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia.
    Eur J Cancer. 2020;142:10-17.
    PubMed     Abstract available
    
    
    October 2020
42. RAUSCHENBACH L, Wieland A, Reinartz R, Kebir S, et al
    Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma.
    Eur J Cancer. 2020;140:130-139.
    PubMed     Abstract available
    
    
    September 2020
43. MORENO L, Barone G, DuBois SG, Molenaar J, et al
    Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
    Eur J Cancer. 2020;136:52-68.
    PubMed     Abstract available
    
    
    July 2020
44. CALLEC L, Lardy-Cleaud A, Guerrini-Rousseau L, Alapetite C, et al
    Relapsing intracranial germ cell tumours warrant retreatment.
    Eur J Cancer. 2020;136:186-194.
    PubMed     Abstract available
    
    
    April 2020
45. TSAKONAS G, Lewensohn R, Botling J, Ortiz-Villalon C, et al
    An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer.
    Eur J Cancer. 2020;132:24-34.
    PubMed     Abstract available
    
    
    March 2020
46. DELUCHE E, Antoine A, Bachelot T, Lardy-Cleaud A, et al
    Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Eur J Cancer. 2020;129:60-70.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: